Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Newsfilter
- Clinical Trial Success: Ziihera demonstrated significant improvement in progression-free survival in the HERIZON-GEA-01 Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, exceeding a four-month increase over the control group, which is expected to drive future regulatory approvals.
- Milestone Payment Potential: Zymeworks stands to earn up to $440 million in milestone payments from regulatory approvals of Ziihera, with $250 million potentially from the U.S. market, highlighting the company's strong growth potential in global markets.
- Share Repurchase Program: The company announced a $125 million share repurchase plan in November 2025, aimed at enhancing shareholder value by reducing share count while maintaining financial flexibility for future growth investments.
- Strong Financial Foundation: As of December 31, 2025, Zymeworks reported approximately $270.6 million in cash and cash equivalents, combined with anticipated milestone payments, expected to support operations beyond 2028, ensuring long-term financial stability.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.10 USD with a low forecast of 25.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.100
Low
25.00
Averages
35.10
High
42.00
Current: 23.100
Low
25.00
Averages
35.10
High
42.00
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
